CytoMed Therapeutics Ltd
GDTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873093
In the last 90 days, CytoMed Therapeutics Ltd insiders filed 1 open-market purchase and 0 sales; 3 institutions reported holding it in 13F filings for Q2 2026, worth $12.2K in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $300.0K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 3
- 13F valueReported value at the end of Q2 2026
- $12.2K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GDTC, Q2 2026
No superinvestor reported holding GDTC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by CytoMed Therapeutics Ltd insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 24, 2026 (view filing)9:01 PM ET | Jul 14-20 | 10 days | Choo Chee KongDirector, 10% Owner | PPurchaseORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED | +200.0K | $1.50 | +$300.0K | +46.5%630.3K after | Amended2 lots |
| Jun 15, 2026 (view filing) | May 13 | 33 daysLate | Choo Chee KongDirector, 10% Owner | PPurchaseOrdinary Shares, no par value per share | +112.0K | $1.15 | +$128.8K | +35.2%430.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in CytoMed Therapeutics Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Axiom Investment Management LLC | 7,032 | $7.24K | 0.00% | +7,032 | New |
| UBS Group AG | 4,831 | $4.98K | 0.00% | −1,351−21.9% | Reduced |
| Advisor Group Holdings, Inc. | 21 | $21 | 0.00% | 00.0% | Unchanged |